Susceptibility to familial cutaneous melanoma
Rare disease
No
- Definition
- A susceptibility or predisposition to cutaneous melanoma (disease) that is caused by an inherited modification of the individual's genome.
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Susceptibility to familial cutaneous melanoma
- susceptibility to familial cutaneous melanoma
- hereditary cutaneous melanoma (disease)
- melanoma, cutaneous malignant
- Severity
- Moderate
- Genetic
- Hereditary
- Syndromic
- MONDO ID
- MONDO:0024462
- Parent condition
- MONDO:0015356
Related records
Broader conditions (13)
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Disease of genetic or genomic mechanism
- Disease susceptibility
- Hereditary disease
- Hereditary neoplastic syndrome
- Human disease
- Inherited disease susceptibility
- Neoplastic disease or syndrome
- Neoplastic syndrome
- Syndromic disease
Narrower conditions (10)
- Melanoma, cutaneous malignant, susceptibility to, 1
- Melanoma, cutaneous malignant, susceptibility to, 2
- Melanoma, cutaneous malignant, susceptibility to, 3
- Melanoma, cutaneous malignant, susceptibility to, 4
- Melanoma, cutaneous malignant, susceptibility to, 5
- Melanoma, cutaneous malignant, susceptibility to, 6
- Melanoma, cutaneous malignant, susceptibility to, 7
- Melanoma, cutaneous malignant, susceptibility to, 8
- Melanoma, cutaneous malignant, susceptibility to, 9
- Tumor predisposition syndrome 3
Trials (17)
- A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
- A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors
- Clinical Genetics Branch Eligibility Screening Survey
- Comparative Microarray Analysis in Primary Cutaneous Malignant Melanoma
- Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
- Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma
- Electrochemotherapy Changes in Tumor Microenvironment of Cutaneous and Subcutaneous Metastases in Melanoma Patients
- EMDR for Fear of Cancer Recurrence in Patients with Familial Melanoma: a Waiting List Control Trial
- Evaluation of Oncoxin-Viusid® in Cutaneous Melanoma
- Genetic Analysis of Familial Melanoma
- Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma
- Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer
- Pancreas Registry and High Risk Registry
- Pancreatic Cancer Screening of High-Risk Individuals in Arkansas
- SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
- Tailored Intervention for Melanoma Patient's Families
- Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome
Drugs in development (1)
- Ergocalciferol Phase 3